Ocular Therapeutix to Present Phase 3 SOL-1 Results May 5, Host Two Investor Fireside Chats
Ocular Therapeutix will present Phase 3 SOL-1 trial results for its intravitreal axitinib hydrogel on May 5 at ARVO 2026 and update its pipeline at additional scientific meetings. CEO Pravin Dugel will host investor fireside chats May 12 at Bank of America conference and May 26 at Stifel’s virtual forum.
1. Upcoming Scientific Presentations
Ocular Therapeutix has scheduled multiple scientific showcases in May 2026, beginning with an Eyecelerator session at ARVO on May 1, followed by a Phase 3 SOL-1 trial presentation on May 5 at ARVO 2026. Additional posters on real-world anti-VEGF utilization and long-term vision outcomes will be presented May 7.
2. Phase 3 SOL-1 Trial Focus
The May 5 session will detail efficacy and safety data for AXPAXLI™ (OTX-TKI), the company’s intravitreal axitinib hydrogel in Phase 3 SOL-1 trials for neovascular AMD. This pivotal analysis could shape expectations for regulatory filings and future commercial plans.
3. Investor Conference Engagement
CEO Pravin Dugel will appear in fireside chats at the Bank of America Health Care Conference on May 12 and at the Stifel Virtual Ophthalmology Forum on May 26. Live webcasts and 30-day replays will be available via the company’s Investor Relations site.